David J. Moss Acquires 10,000 Shares of INmune Bio, Inc. (NASDAQ:INMB) Stock

INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss purchased 10,000 shares of INmune Bio stock in a transaction on Monday, September 30th. The stock was bought at an average price of $5.29 per share, for a total transaction of $52,900.00. Following the completion of the acquisition, the chief financial officer now owns 1,285,869 shares in the company, valued at approximately $6,802,247.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

INmune Bio Stock Up 2.2 %

INmune Bio stock opened at $5.51 on Wednesday. The company’s 50-day moving average price is $6.67 and its 200-day moving average price is $8.70. INmune Bio, Inc. has a twelve month low of $4.81 and a twelve month high of $14.74. The company has a market cap of $109.00 million, a PE ratio of -2.82 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Institutional Trading of INmune Bio

Large investors have recently made changes to their positions in the business. Rhumbline Advisers bought a new stake in shares of INmune Bio in the 2nd quarter worth about $121,000. Fermata Advisors LLC boosted its stake in shares of INmune Bio by 6.9% during the 1st quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock worth $370,000 after purchasing an additional 2,025 shares during the period. Westside Investment Management Inc. boosted its stake in shares of INmune Bio by 31.8% during the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after purchasing an additional 10,950 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the period. Finally, Marshall Wace LLP boosted its stake in shares of INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the period. 12.72% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Scotiabank assumed coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price target on the stock. Raymond James assumed coverage on shares of INmune Bio in a report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price target on the stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.